While reviewing how 2019 fared for the UK-based lateral flow assay manufacturer, Abingdon Health looks forward to the continuing evolution of the lateral flow diagnostics industry in 2020 and beyond.
2019 started with positive momentum following investment from NPIF – Mercia Equity Finance, which is managed by Mercia Fund Managers and part of the Northern Powerhouse Investment Fund. This investment came following significant confidence shown in the future of lateral flow diagnostics, particularly in the area of Smartphone readers; as well as Abingdon Health’s position within the Industry.
Throughout the year Abingdon Health grew its team by approximately 20% and increased its footprint by approximately 42% at its lateral flow manufacturing facility located in York, UK.
Greater demand for lateral flow immunoassay technology, and increased support, resulted in Abingdon Health being able to expand resources. Meaning all clients, current and new, will continue to take advantage of Abingdon Health’s capabilities.
Recognition of growth was highlighted when Abingdon Health was presented with a business award for being the highest climber among a list of 100 companies based in the North of England.
Abingdon Health further committed to responsibly managing its impact on the environment. In October 2019, the Company announced it was now offering its manufacturing customers the option of using compostable lateral flow housings. Abingdon Health also announced its internal products would move to using the plant-based housing material.
The new lateral flow housing material will emit 50% less C02 during incineration, is compostable to EN 13432 and uses 85% renewable material.
During Medica 2019, visitors took the opportunity to view Abingdon Health’s adaptable rapid test mHealth technology, AppDx. Throughout the exhibition demonstrations were performed to companies looking to capitalise on using Smartphone readers to capture and share lab-quality rapid data from lateral flow tests.
Abingdon Health look to attend Medica again in 2020.
In addition, the Team raised approximately £1,300 for Abingdon Health’s charity partners, St Mary’s Hospice Birmingham and Sands, stillbirth and neonatal death charity.
In 2018 we highlighted why the lateral flow market would grow, stating the evolution of lateral flow assay and reader technology, in particular Smartphone readers, would allow professionals, even in regulated markets, to meet ever changing demands.
2020 is proving our predictions to be correct as we continue to see an increase in lateral flow usage with data capture and sharing via Smartphone readers helping to drive this growth trend.
The future of the lateral assay is positive and the adaptable and easy-to-use technology will continue to be an important factor in helping to improve health outcomes.
2020 and beyond will be a defining decade in the provision of personalised medicine and eHealth solutions, with lateral flow testing a key vehicle for the technology.